Aprea Therapeutics, Inc.
APRE
$1.59
-$0.0324-2.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 157.60% | 130.31% | 410.93% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 157.60% | 130.31% | 410.93% | -- | -- |
| Cost of Revenue | 22.76% | 48.04% | 63.00% | -17.97% | -9.85% |
| Gross Profit | -11.60% | -39.60% | -45.12% | 27.88% | 16.74% |
| SG&A Expenses | -23.36% | -21.06% | -30.42% | -71.11% | -66.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.45% | 7.07% | 0.61% | -55.89% | -57.04% |
| Operating Income | 7.45% | -2.21% | 6.16% | 58.73% | 58.60% |
| Income Before Tax | 9.30% | -1.67% | 8.35% | 88.34% | 87.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.30% | -1.67% | 8.35% | 88.34% | 87.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.30% | -1.67% | 8.35% | 88.34% | 87.32% |
| EBIT | 7.45% | -2.21% | 6.16% | 58.73% | 58.60% |
| EBITDA | 7.55% | -2.08% | 6.27% | 58.76% | 58.61% |
| EPS Basic | 40.52% | 29.63% | 44.46% | 96.36% | 95.89% |
| Normalized Basic EPS | 40.52% | 29.63% | 44.46% | 86.28% | 86.73% |
| EPS Diluted | 40.52% | 29.63% | 44.46% | 96.36% | 95.89% |
| Normalized Diluted EPS | 40.52% | 29.63% | 44.46% | 86.28% | 86.73% |
| Average Basic Shares Outstanding | 52.31% | 48.11% | 54.80% | 75.51% | 118.81% |
| Average Diluted Shares Outstanding | 52.31% | 48.11% | 54.80% | 75.51% | 118.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |